000120659 001__ 120659
000120659 005__ 20240228145459.0
000120659 0247_ $$2pmid$$apmid:28174141
000120659 0247_ $$2ISSN$$a1167-1122
000120659 0247_ $$2ISSN$$a1952-4013
000120659 0247_ $$2altmetric$$aaltmetric:28164970
000120659 037__ $$aDKFZ-2017-01086
000120659 041__ $$aeng
000120659 082__ $$a610
000120659 1001_ $$aThierauf, Julia$$b0
000120659 245__ $$aCheckpoint inhibition for advanced mucosal melanoma.
000120659 260__ $$aMontrouge$$bLibbey Eurotext$$c2017
000120659 3367_ $$2DRIVER$$aarticle
000120659 3367_ $$2DataCite$$aOutput Types/Journal article
000120659 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511255091_9877
000120659 3367_ $$2BibTeX$$aARTICLE
000120659 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120659 3367_ $$00$$2EndNote$$aJournal Article
000120659 520__ $$aWhereas anti-PD-1 therapy has demonstrated a significant and durable response against advanced cutaneous melanoma, conventional chemotherapies have shown only minor benefit against advanced mucosal melanoma.To investigate the efficacy of anti-PD-1 therapy in a small cohort of patients with mucosal melanoma of the head and neck.We analysed five patients with mucosal melanoma of the head and neck who received nivolumab or pembrolizumab, at an advanced stage. Expression of PD-L1 and PD-1 in all tumour samples was evaluated immunohistochemically.All patients received at least two cycles of nivolumab or pembrolizumab. The most severe adverse events were categorised as CTCAE (common terminology criteria for adverse events) Grade 2. All patients showed progressive disease after restaging at three and six months, and no partial or complete response was observed. Immunohistochemical staining demonstrated PD-L1 expression in less than 5% of tumour cells.Systemic therapy with either nivolumab or pembrolizumab showed no clinical response, however, tumour progression was identified in all patients using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 and immune-related response criteria (irRC) to evaluate tumour response.
000120659 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000120659 588__ $$aDataset connected to PubMed,
000120659 7001_ $$aVeit, Johannes A$$b1
000120659 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b2$$udkfz
000120659 7001_ $$aTreiber, Nicolai$$b3
000120659 7001_ $$aLisson, Catharina$$b4
000120659 7001_ $$aWeissinger, Stephanie E$$b5
000120659 7001_ $$aBommer, Martin$$b6
000120659 7001_ $$aHoffmann, Thomas K$$b7
000120659 773__ $$0PERI:(DE-600)2041476-6$$gVol. 27, no. 2$$n2$$p160-165$$tEuropean journal of dermatology$$v27$$x1167-1122$$y2017
000120659 909CO $$ooai:inrepo02.dkfz.de:120659$$pVDB
000120659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120659 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000120659 9141_ $$y2017
000120659 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120659 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120659 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J DERMATOL : 2015
000120659 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120659 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120659 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120659 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120659 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120659 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120659 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120659 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120659 9201_ $$0I:(DE-He78)G405-20160331$$kG405$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000120659 980__ $$ajournal
000120659 980__ $$aVDB
000120659 980__ $$aI:(DE-He78)G405-20160331
000120659 980__ $$aUNRESTRICTED